Clinical Trial Update: A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Abicipar Pegol for neovascular age-related macular degeneration. The study is completed and results were posted on 2016-04-05.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Abicipar Pegol (Abicipar Pegol)

Snippet

Sponsor: Allergan | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2016-04-05